A Phase 4 interventional study of Zolpidem and Internet Cognitive Behavioral Therapy for Insomnia (CBT-I) in Chronic Insomnia, sponsored by California Pacific Medical Center Research Institute. Completed at 7 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-02-24.
Sponsored by California Pacific Medical Center Research Institute · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies testing zolpidem in Sleep Initiation and Maintenance Disorders — 2 open to participants now, 2 under way, 1 of them phase 3. Zolpidem · Sleep Initiation and Maintenance Disorders.
Among the 40 studies testing zolpidem in Sleep Initiation and Maintenance Disorders, this one is the 11th largest by enrollment, is the only one that started in 2022, is one of 19 in phase 4, and was the 37th registered.
2,738 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 735 are open to participants now.
Browse Sleep Initiation and Maintenance Disorders studies →2 of the 40 studies testing zolpidem in Sleep Initiation and Maintenance Disorders are open now, in 1 country. Recruiting first, the newest first:
Emory University · Sites in United States
Ages 18–65
University of Pennsylvania · Sites in United States
Ages 18–80
By country, each count listing its studies:
Zolpidem: first FDA approval 1992 (AMBIEN). What it is approved for, and how studies give it, is on its page →
Of the 394 Sleep Initiation and Maintenance Disorders studies recruiting now, 156 (40%) set no upper age limit and 208 (53%) stop at 75 or younger; 61 take children under 18; 112 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 8 · Phase 3 7 · Phase 4 19
First in 2001; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 155 is above the median of 68 across 2,363 interventional studies indexed under Sleep Initiation and Maintenance Disorders.
Median enrollment 108 across the 40 interventional studies. Of the 37 that completed or were terminated, 14 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 40 have an industry lead sponsor. The 10 most frequent:
California Pacific Medical Center Research Institute is the lead sponsor of 39 studies on the registry; 3 are open to participants now.
California Pacific Medical Center Research Institute has 1 study filed under Sleep Initiation and Maintenance Disorders — fewer than ten, so there is no comparison to draw.
1 of the studies testing zolpidem in Sleep Initiation and Maintenance Disorders that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07336277Phase 3Emory UniversitySleep Quality and the Efficacy of a Multimodal Sleep Pathway in Hospitalized Orthopedic Trauma Patients | 2027-07 |
Add it to your calendar (.ics) → With an account.
Among the 40 studies testing zolpidem in Sleep Initiation and Maintenance Disorders, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is a randomized (1:1:1) comparative effectiveness trial of medication (zolpidem or trazodone), cognitive-behavioral therapy for insomnia (CBT-I), and the combination (medication + CBT-I) for the treatment of chronic insomnia in men and women aged 18-80 living in rural areas with 1 year of follow-up. A total of 155 participants will be enrolled and randomized in the United States. This trial is funded by the Patient-Centered Outcomes Research Institute.
Insomnia is a common health problem that causes distress, impaired function, and increased risk for other health problems. Chronic insomnia is defined by problems with the quality or amount of sleep, including difficulty falling asleep, frequent awakenings, and/or awakening early and being unable to return to sleep. In developing this application, patients, providers, payors, and the investigators identified both concerns and opportunities with current treatments for chronic insomnia. Medications and Cognitive-Behavioral therapy for insomnia (CBT-I; a treatment program to improve sleep through changes in behavior and thinking) are both effective for treating insomnia. Zolpidem, the most frequently prescribed insomnia medication, is widely available, but may cause side effects and dependency. Trazodone is increasingly prescribed off-label for treatment of insomnia, but evidence of efficacy and safety is more limited. CBT-I is the recommended first line treatment by many professional organizations, but it is not widely available in physicians' practices. Patients, providers, and payors face important unanswered questions: Which treatment should be used for the treatment of chronic insomnia? Is combination therapy more effective, and does it result in lower zolpidem use? Who responds best to which treatment? These dilemmas are particularly relevant to patients and providers in rural areas, where access to behavioral health specialists is limited, and concerns regarding use of controlled substances is particularly acute.
To address these questions, we propose the study, Comparative Effectiveness of Zolpidem/Trazodone and Cognitive Behavioral Therapy for Insomnia in Rural Adults (COZI). The investigators will use a well-tested Internet version of CBT-I, which is just as effective as in-person CBT-I, but more widely available. The aims of COZI are to: 1: Compare the effectiveness of medication preference (zolpidem or trazodone), CBT-I, and combination treatment for insomnia symptoms over 6 months. 2: Compare the effectiveness of medication preference, CBT-I, and combination treatment for other symptoms and problems, including health-related quality of life, mood, and health outcomes. 3: Compare the side effects of medication preference, CBT-I, and combination treatment. COZI will study 155 patients recruited from 7 health care systems across the country, each of which has established practices in rural areas. Patients will be treated with medication prescribed by their own physician (zolpidem or trazodone), Internet CBT-I, or a combination of the two. The investigators will evaluate treatment effects at 9 weeks, and 6 and 12 months (with limited additional assessments for adverse events and medication use at 1 and 9 months). Our study questions and design reflect early and ongoing engagement of key stakeholders including patients, providers, and payors, who are members of the Study Advisory Committee (SAC). SAC members will work with study investigators to recommend the best strategies for recruiting patients, measuring treatment effects, and disseminating study findings. The SAC will meet quarterly. Patients and other stakeholders have already provided guidance on which treatments are most worth studying, and which symptoms would best reflect the effects of treatment. Patients and other stakeholders will also be part of the Steering Committee, which is the main decision-making group for our study, and which will meet monthly. COZI will lead to answers for patients and providers addressing insomnia; improved health and function for millions of rural Americans; and sustainable changes in how insomnia is treated in rural practices.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Zolpidem or trazodone, as prescribed by physician
Drug: Zolpidem · Drug: Trazodone
Internet-based CBT-I program
Behavioral: Internet Cognitive Behavioral Therapy for Insomnia (CBT-I)
Medication (zolpidem or trazodone) as prescribed by physician and Internet-based CBT-I program
Drug: Zolpidem · Behavioral: Internet Cognitive Behavioral Therapy for Insomnia (CBT-I) · Drug: Trazodone
Zolpidem, as prescribed by physician
Also known as: Ambien
6-week internet CBT-I multi-component intervention (SHUTi) including sleep restriction, stimulus control, cognitive restructuring, sleep behaviors, and relapse prevention
Also known as: SHUTi
Trazodone, as prescribed by physician
Also known as: Desyrel
Change in Insomnia Symptom Severity
Change in Insomnia Severity Index score from baseline to follow-up. The Insomnia Severity Index is a 7-item self-report questionnaire that measures severity of insomnia symptoms during the last two weeks. Each item is scored 0 (no problem) to 4 (very severe problem) and total between 0-28, with higher scores indicating more severe insomnia symptoms. Change is estimated mean change from mixed-effects linear regression model. Fixed effects: Baseline ISI, Treatment Arm, Visit and Treatment Arm\*Visit interaction. Random effects: intercept for Subject, nested within Site.
Time frame: Baseline, 6 months
Number of Participants With Treatment Response of Insomnia Symptoms
Treatment response defined as a ≥6 point reduction in Insomnia Severity Index score from baseline to follow-up. The Insomnia Severity Index is a 7-item self-report questionnaire that measures severity of insomnia symptoms during the last two weeks. Each item is scored 0 (no problem) to 4 (very severe problem) and total between 0-28, with higher scores indicating more severe insomnia symptoms. Data presented as count of participants meeting treatment response criteria at 6 months.
Time frame: Baseline, 6 months
Number of Participants With Remission of Insomnia Symptoms
Remission of Insomnia symptoms defined as Insomnia Severity Index \<8 at follow-up. The Insomnia Severity Index is a 7-item self-report questionnaire that measures severity of insomnia symptoms during the last two weeks. Each item is scored 0 (no problem) to 4 (very severe problem) and total between 0-28, with higher scores indicating more severe insomnia symptoms. Data presented as count of participants meeting insomnia remission criteria at 6 months.
Time frame: 6 months
Change in Anxiety and Depression
The Patient Health Questionnaire (PHQ-8) is an 8-item self-report measure for assessing depression severity. The items are summed to yield a score between 0 and 24, with higher scores indicating more frequent depression symptoms. The Generalized Anxiety Disorder (GAD-7) Scale is a 7-item self-report measure used for screening and assessing severity of GAD. The items are summed to yield a score between 0 and 21, with higher scores indicating more severe GAD symptoms. Change is estimated mean change in mixed-effects linear regression model. Fixed effects: Treatment Arm, Visit and Treatment Arm\*Visit interaction. Random effects: intercept for Subject, nested within Site.
Time frame: Baseline, 6 months
Change in Cognitive Function
The PROMIS Cognitive Function Short Form (8a) is an 8-item self-report measure related to executive functioning. Individual item responses range from 1 (very often) to 5 (never) and the total raw score is converted to standardized T-scores using established United States general adult population with a mean of 50 and a standard deviation of 10. Higher T-scores signify better cognitive function. Estimated mean change in T-score from baseline to follow-up is reported from mixed-effects linear regression model. Fixed effects: Treatment Arm, Visit and Treatment Arm\*Visit interaction. Random effects: intercept for Subject, nested within Site. Positive change indicates improved cognitive function.
Time frame: Baseline, 6 months
Change in Patient-Reported Health
The PROMIS Global Health is a 10-item self-report measure that assess general health and functioning. Item responses range from 1 (excellent/none) to 5 (poor/always) and a single pain item ranges from 0 (no pain) to 10 (worst pain). Physical and mental health sub-scores are calculated from 4 items each, and the total raw sub-scores (range: 4-20) are converted to T-scores using distributions standardized to mean 50 (SD 10) for the US general population. Higher score indicates greater health-related quality of life. The Medical Outcome Survey (SF-12) is a 12-item self-report measure of physical and mental health. The Physical Component Score (PCS) and Mental Component Score (MCS) sub-scores range 0-100; higher score indicates better health. Change is estimated mean change from baseline to follow-up in mixed-effects linear regression model. Fixed effects: Treatment Arm, Visit and Treatment Arm\*Visit interaction. Random effects: intercept for Subject, nested within Site.
Time frame: Baseline, 6 months
Change in Fatigue
The PROMIS Fatigue instrument is a 7-item self-report measure that assesses recent fatigue and how fatigue interfered with daily activities. Scores range from 7 to 35, with higher scores indicating greater fatigue. Change is estimated mean change from mixed-effects linear regression model. Fixed effects: Treatment Arm, Visit and Treatment Arm\*Visit interaction. Random effects: intercept for Subject, nested within Site.
Time frame: Baseline, 6 months
Change in Pain Intensity and Interference
The PROMIS Pain Intensity scale is a 3-item instrument used to assess how much pain a person has. Scores range from 3-15, with higher scores indicating greater pain intensity. The PROMIS Pain Interference scale is a 6-item instrument used to assess the consequences of pain in different domains of daily life. Scores range from 6-30, with higher scores indicating greater interference. Change is estimated mean change from mixed-effects linear regression model. Fixed effects: Treatment Arm, Visit and Treatment Arm\*Visit interaction. Random effects: intercept for Subject, nested within Site.
Time frame: Baseline, 6 months
Change in Pittsburgh Sleep Quality Index
The Pittsburgh Sleep Quality Index (PSQI) is an 18-item self-report measure that assesses sleep quality in the past month. These items are combined into seven component scores (subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbance, use of sleep medication, and daytime dysfunction). The seven component scores are added to produce a global sleep quality score ranging from 0 to 21; higher total score indicates worse sleep quality. Change is estimated mean change from mixed-effects linear regression model. Fixed effects: Treatment Arm, Visit and Treatment Arm\*Visit interaction. Random effects: intercept for Subject, nested within Site.
Time frame: Baseline, 6 months
Change in Daytime Sleepiness
The Epworth Sleepiness Scale (ESS) is an 8-item self-report measure that assesses daytime sleepiness by asking about the likelihood of dozing in certain situations. Individual items are summed to yield the ESS score between 0 (never doze) to 24 (doze a lot) with higher scores indicating more sleepiness. Change is estimated mean change from mixed-effects linear regression model. Fixed effects: Treatment Arm, Visit and Treatment Arm\*Visit interaction. Random effects: intercept for Subject, nested within Site.
Time frame: Baseline, 6 months
Change in Munich Chronotype
The Munich Chronotype Questionnaire (MCTQ) is a self-report scale to assess sleep structure, patterns, duration, and quality. The chronotype sub-score represents the mid-point time of sleep which is converted to a numeric value by adding the hour plus minutes divided by 60. Greater values indicate later chronotype. Positive change values indicate a shift to later chronotype. Change is estimated mean change from mixed-effects linear regression model. Fixed effects: Treatment Arm, Visit and Treatment Arm\*Visit interaction. Random effects: intercept for Subject, nested within Site.
Time frame: Baseline, 6 months
Dysfunctional Beliefs and Attitudes About Sleep
Dysfunctional Beliefs and Attitudes about Sleep (DBAS) Scale is a 16-item instrument used to evaluate dysfunctional thoughts related to insomnia. Each item is scored 0-10 and the total is the average of the 16 item scores (range 0-10), with higher scores indicating greater dysfunctional beliefs about sleep.
Time frame: Baseline, 6 months
Number of Participants With Insomnia Treatment Side Effects
Side effects (frequency, severity, impairment) are recorded via self-report adapted from the FIBSER. Scores range from 0 (no side effects; better) to 21 (worse). Side effects were analyzed if participant reported severity of greater than moderate and/or frequency greater than 50% of the time. Count of participants meeting the threshold for analysis up through the 6 month follow-up.
Time frame: 1 month, 9 weeks, 6 months
Medication Adherence
Medication use is assessed using self-reported prescription, over-the-counter, and supplement name and frequency. Count of participants reporting zolpidem or trazodone use for sleep is recorded for adherence to the Medication and Combination treatment arms.
Time frame: 1 month, 9 weeks, 6 months, 9 months, 12 months
Self-reported Falls
Participants self-reported number of falls including context, location, and consequences of falls. Count of participants with one or more falls up through the 6 month follow-up.
Time frame: 1 month, 9 weeks, 6 months
| Milestone | Medication (Zolpidem or Trazodone) | Internet Cognitive Behavioral Therapy for Insomnia (CBT-I) | Combination |
|---|---|---|---|
| Started | 49 | 54 | 52 |
| 9 weeks follow-up | 40 | 37 | 41 |
| 6 months follow-up | 38 | 32 | 34 |
| 12 months follow-up | 37 | 30 | 33 |
| Completed | 44 | 40 | 43 |
| Not completed | 5 | 14 | 9 |
| Withdrew: Lost to follow-up | 4 | 3 | 4 |
| Withdrew: Withdrawal by subject | 1 | 10 | 4 |
| Withdrew: Physician decision | 0 | 1 | 1 |
Change in Insomnia Severity Index score from baseline to follow-up. The Insomnia Severity Index is a 7-item self-report questionnaire that measures severity of insomnia symptoms during the last two weeks. Each item is scored 0 (no problem) to 4 (very severe problem) and total between 0-28, with higher scores indicating more severe insomnia symptoms. Change is estimated mean change from mixed-effects linear regression model. Fixed effects: Baseline ISI, Treatment Arm, Visit and Treatment Arm\*Visit interaction. Random effects: intercept for Subject, nested within Site.
| change score on a scale | Medication (Zolpidem or Trazodone) | Internet Cognitive Behavioral Therapy for Insomnia (CBT-I) | Combination |
|---|---|---|---|
| Change in Insomnia Symptom Severity | -8.05 (-9.44 to -6.65) | -7.82 (-9.32 to -6.32) | -10.19 (-11.66 to -8.73) |
Treatment response defined as a ≥6 point reduction in Insomnia Severity Index score from baseline to follow-up. The Insomnia Severity Index is a 7-item self-report questionnaire that measures severity of insomnia symptoms during the last two weeks. Each item is scored 0 (no problem) to 4 (very severe problem) and total between 0-28, with higher scores indicating more severe insomnia symptoms. Data presented as count of participants meeting treatment response criteria at 6 months.
| Participants | Medication (Zolpidem or Trazodone) | Internet Cognitive Behavioral Therapy for Insomnia (CBT-I) | Combination |
|---|---|---|---|
| Number of Participants With Treatment Response of Insomnia Symptoms | 22 | 21 | 31 |
Remission of Insomnia symptoms defined as Insomnia Severity Index \<8 at follow-up. The Insomnia Severity Index is a 7-item self-report questionnaire that measures severity of insomnia symptoms during the last two weeks. Each item is scored 0 (no problem) to 4 (very severe problem) and total between 0-28, with higher scores indicating more severe insomnia symptoms. Data presented as count of participants meeting insomnia remission criteria at 6 months.
| Participants | Medication (Zolpidem or Trazodone) | Internet Cognitive Behavioral Therapy for Insomnia (CBT-I) | Combination |
|---|---|---|---|
| Number of Participants With Remission of Insomnia Symptoms | 16 | 13 | 16 |
The Patient Health Questionnaire (PHQ-8) is an 8-item self-report measure for assessing depression severity. The items are summed to yield a score between 0 and 24, with higher scores indicating more frequent depression symptoms. The Generalized Anxiety Disorder (GAD-7) Scale is a 7-item self-report measure used for screening and assessing severity of GAD. The items are summed to yield a score between 0 and 21, with higher scores indicating more severe GAD symptoms. Change is estimated mean change in mixed-effects linear regression model. Fixed effects: Treatment Arm, Visit and Treatment Arm\*Visit interaction. Random effects: intercept for Subject, nested within Site.
| change score on a scale | Medication (Zolpidem or Trazodone) | Internet Cognitive Behavioral Therapy for Insomnia (CBT-I) | Combination |
|---|---|---|---|
| Patient Health Questionnaire (PHQ-8) | -2.37 (-3.39 to -1.36) | -2.74 (-3.87 to -1.61) | -4.63 (-5.7 to -3.56) |
| Generalized Anxiety Disorder (GAD-7) | -1.24 (-2.26 to -0.23) | -2.16 (-3.29 to -1.03) | -2.34 (-3.4 to -1.27) |
The PROMIS Cognitive Function Short Form (8a) is an 8-item self-report measure related to executive functioning. Individual item responses range from 1 (very often) to 5 (never) and the total raw score is converted to standardized T-scores using established United States general adult population with a mean of 50 and a standard deviation of 10. Higher T-scores signify better cognitive function. Estimated mean change in T-score from baseline to follow-up is reported from mixed-effects linear regression model. Fixed effects: Treatment Arm, Visit and Treatment Arm\*Visit interaction. Random effects: intercept for Subject, nested within Site. Positive change indicates improved cognitive function.
| T-score | Medication (Zolpidem or Trazodone) | Internet Cognitive Behavioral Therapy for Insomnia (CBT-I) | Combination |
|---|---|---|---|
| Change in Cognitive Function | 2.87 (0.81 to 4.93) | 6.64 (4.36 to 8.93) | 4.58 (2.42 to 6.74) |
The PROMIS Global Health is a 10-item self-report measure that assess general health and functioning. Item responses range from 1 (excellent/none) to 5 (poor/always) and a single pain item ranges from 0 (no pain) to 10 (worst pain). Physical and mental health sub-scores are calculated from 4 items each, and the total raw sub-scores (range: 4-20) are converted to T-scores using distributions standardized to mean 50 (SD 10) for the US general population. Higher score indicates greater health-related quality of life. The Medical Outcome Survey (SF-12) is a 12-item self-report measure of physical and mental health. The Physical Component Score (PCS) and Mental Component Score (MCS) sub-scores range 0-100; higher score indicates better health. Change is estimated mean change from baseline to follow-up in mixed-effects linear regression model. Fixed effects: Treatment Arm, Visit and Treatment Arm\*Visit interaction. Random effects: intercept for Subject, nested within Site.
| change score on a scale | Medication (Zolpidem or Trazodone) | Internet Cognitive Behavioral Therapy for Insomnia (CBT-I) | Combination |
|---|---|---|---|
| Global Health: Mental | 1.22 (-0.52 to 2.95) | 2.43 (0.49 to 4.37) | 4.01 (2.18 to 5.83) |
| Global Health: Physical | 2.87 (1.22 to 4.52) | 2.51 (0.68 to 4.35) | 3.59 (1.86 to 5.32) |
| SF-12 Physical Component Score | 2.92 (0.75 to 5.09) | 0.07 (-2.33 to 2.46) | 1.92 (-0.34 to 4.18) |
| SF-12 Mental Component Score | -0.11 (-2.85 to 2.63) | 4.39 (1.38 to 7.4) | 4.46 (1.61 to 7.3) |
The PROMIS Fatigue instrument is a 7-item self-report measure that assesses recent fatigue and how fatigue interfered with daily activities. Scores range from 7 to 35, with higher scores indicating greater fatigue. Change is estimated mean change from mixed-effects linear regression model. Fixed effects: Treatment Arm, Visit and Treatment Arm\*Visit interaction. Random effects: intercept for Subject, nested within Site.
| change score on a scale | Medication (Zolpidem or Trazodone) | Internet Cognitive Behavioral Therapy for Insomnia (CBT-I) | Combination |
|---|---|---|---|
| Change in Fatigue | -5.44 (-7.99 to -2.89) | -8.82 (-11.66 to -5.99) | -6.8 (-9.48 to -4.12) |
The PROMIS Pain Intensity scale is a 3-item instrument used to assess how much pain a person has. Scores range from 3-15, with higher scores indicating greater pain intensity. The PROMIS Pain Interference scale is a 6-item instrument used to assess the consequences of pain in different domains of daily life. Scores range from 6-30, with higher scores indicating greater interference. Change is estimated mean change from mixed-effects linear regression model. Fixed effects: Treatment Arm, Visit and Treatment Arm\*Visit interaction. Random effects: intercept for Subject, nested within Site.
| change score on a scale | Medication (Zolpidem or Trazodone) | Internet Cognitive Behavioral Therapy for Insomnia (CBT-I) | Combination |
|---|---|---|---|
| Pain Intensity | -0.55 (-2.7 to 1.6) | -1.72 (-4.13 to 0.68) | -3.84 (-6.11 to -1.58) |
| Pain Interference | -1.81 (-4.26 to 0.63) | 0.72 (-2.01 to 3.44) | -3.73 (-6.3 to -1.16) |
The Pittsburgh Sleep Quality Index (PSQI) is an 18-item self-report measure that assesses sleep quality in the past month. These items are combined into seven component scores (subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbance, use of sleep medication, and daytime dysfunction). The seven component scores are added to produce a global sleep quality score ranging from 0 to 21; higher total score indicates worse sleep quality. Change is estimated mean change from mixed-effects linear regression model. Fixed effects: Treatment Arm, Visit and Treatment Arm\*Visit interaction. Random effects: intercept for Subject, nested within Site.
| change score on a scale | Medication (Zolpidem or Trazodone) | Internet Cognitive Behavioral Therapy for Insomnia (CBT-I) | Combination |
|---|---|---|---|
| Change in Pittsburgh Sleep Quality Index | -3.42 (-4.46 to -2.38) | -4.52 (-5.67 to -3.37) | -5.23 (-6.32 to -4.15) |
The Epworth Sleepiness Scale (ESS) is an 8-item self-report measure that assesses daytime sleepiness by asking about the likelihood of dozing in certain situations. Individual items are summed to yield the ESS score between 0 (never doze) to 24 (doze a lot) with higher scores indicating more sleepiness. Change is estimated mean change from mixed-effects linear regression model. Fixed effects: Treatment Arm, Visit and Treatment Arm\*Visit interaction. Random effects: intercept for Subject, nested within Site.
| change score on a scale | Medication (Zolpidem or Trazodone) | Internet Cognitive Behavioral Therapy for Insomnia (CBT-I) | Combination |
|---|---|---|---|
| Change in Daytime Sleepiness | -2.81 (-3.77 to -1.84) | -2.61 (-3.68 to -1.54) | -2.18 (-3.2 to -1.17) |
The Munich Chronotype Questionnaire (MCTQ) is a self-report scale to assess sleep structure, patterns, duration, and quality. The chronotype sub-score represents the mid-point time of sleep which is converted to a numeric value by adding the hour plus minutes divided by 60. Greater values indicate later chronotype. Positive change values indicate a shift to later chronotype. Change is estimated mean change from mixed-effects linear regression model. Fixed effects: Treatment Arm, Visit and Treatment Arm\*Visit interaction. Random effects: intercept for Subject, nested within Site.
| hours | Medication (Zolpidem or Trazodone) | Internet Cognitive Behavioral Therapy for Insomnia (CBT-I) | Combination |
|---|---|---|---|
| Change in Munich Chronotype | 0.08 (-0.16 to 0.33) | -0.02 (-.029 to 0.24) | 0.23 (-0.03 to 0.5) |
Dysfunctional Beliefs and Attitudes about Sleep (DBAS) Scale is a 16-item instrument used to evaluate dysfunctional thoughts related to insomnia. Each item is scored 0-10 and the total is the average of the 16 item scores (range 0-10), with higher scores indicating greater dysfunctional beliefs about sleep.
| score on a scale | Medication (Zolpidem or Trazodone) | Internet Cognitive Behavioral Therapy for Insomnia (CBT-I) | Combination |
|---|---|---|---|
| Baseline DBAS mean total score | 6.1 ± 1.8 | 6.0 ± 1.3 | 6.2 ± 1.7 |
| 6 months DBAS mean total score | 5.4 ± 1.8 | 4.2 ± 1.6 | 4.0 ± 2.1 |
Side effects (frequency, severity, impairment) are recorded via self-report adapted from the FIBSER. Scores range from 0 (no side effects; better) to 21 (worse). Side effects were analyzed if participant reported severity of greater than moderate and/or frequency greater than 50% of the time. Count of participants meeting the threshold for analysis up through the 6 month follow-up.
| Participants | Medication (Zolpidem or Trazodone) | Internet Cognitive Behavioral Therapy for Insomnia (CBT-I) | Combination |
|---|---|---|---|
| Number of Participants With Insomnia Treatment Side Effects | 16 | 13 | 15 |
Medication use is assessed using self-reported prescription, over-the-counter, and supplement name and frequency. Count of participants reporting zolpidem or trazodone use for sleep is recorded for adherence to the Medication and Combination treatment arms.
| Participants | Medication (Zolpidem or Trazodone) | Combination |
|---|---|---|
| Medication Adherence | 38 | 28 |
Participants self-reported number of falls including context, location, and consequences of falls. Count of participants with one or more falls up through the 6 month follow-up.
| Participants | Medication (Zolpidem or Trazodone) | Internet Cognitive Behavioral Therapy for Insomnia (CBT-I) | Combination |
|---|---|---|---|
| Self-reported Falls | 8 | 3 | 7 |
Collected over 12 months. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Medication (Zolpidem) | 0/11 (0%) | 1/11 (9.1%) | 4/11 (36.4%) |
| Medication (Trazodone) | 0/38 (0%) | 0/38 (0%) | 10/38 (26.3%) |
| Internet Cognitive Behavioral Therapy for Insomnia (CBT-I) | 0/54 (0%) | 2/54 (3.7%) | 6/54 (11.1%) |
| Combination (Zolpidem) | 0/11 (0%) | 0/11 (0%) | 2/11 (18.2%) |
| Combination (Trazodone) | 0/41 (0%) | 0/41 (0%) | 7/41 (17.1%) |
| Event | Medication (Zolpidem) | Medication (Trazodone) | Internet Cognitive Behavioral Therapy for Insomnia (CBT-I) | Combination (Zolpidem) | Combination (Trazodone) |
|---|---|---|---|---|---|
| Urinary tract infectionInfections and infestations | 1/11 | 0/38 | 0/54 | 0/11 | 0/41 |
| SomnolenceNervous system disorders | 0/11 | 0/38 | 1/54 | 0/11 | 0/41 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 0/11 | 0/38 | 1/54 | 0/11 | 0/41 |
| Event | Medication (Zolpidem) | Medication (Trazodone) | Internet Cognitive Behavioral Therapy for Insomnia (CBT-I) | Combination (Zolpidem) | Combination (Trazodone) |
|---|---|---|---|---|---|
| DizzinessNervous system disorders | 2/11 | 0/38 | 0/54 | 0/11 | 1/41 |
| SomnolenceNervous system disorders | 1/11 | 6/38 | 5/54 | 2/11 | 3/41 |
| FallInjury, poisoning and procedural complications | 1/11 | 2/38 | 2/54 | 0/11 | 4/41 |
| PalpatationsCardiac disorders | 1/11 | 0/38 | 0/54 | 0/11 | 0/41 |
| ArthritisMusculoskeletal and connective tissue disorders | 1/11 | 0/38 | 0/54 | 0/11 | 0/41 |
| HeadacheNervous system disorders | 1/11 | 2/38 | 0/54 | 0/11 | 1/41 |
| ConfusionNervous system disorders | 1/11 | 0/38 | 0/54 | 0/11 | 0/41 |
| Age, Continuous(years) | Medication (Zolpidem or Trazodone) | Internet Cognitive Behavioral Therapy for Insomnia (CBT-I) | Combination | Total |
|---|---|---|---|---|
| Mean | 55.2 ± 14.6 | 52.5 ± 15.3 | 52.5 ± 15.3 | 53.4 ± 15.0 |
| Sex: Female, Male(Participants) | Medication (Zolpidem or Trazodone) | Internet Cognitive Behavioral Therapy for Insomnia (CBT-I) | Combination | Total |
|---|---|---|---|---|
| Female | 37 | 44 | 37 | 118 |
| Male | 12 | 10 | 14 | 36 |
| Ethnicity (NIH/OMB)(Participants) | Medication (Zolpidem or Trazodone) | Internet Cognitive Behavioral Therapy for Insomnia (CBT-I) | Combination | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 3 | 4 |
| Not Hispanic or Latino | 48 | 54 | 49 | 151 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Medication (Zolpidem or Trazodone) | Internet Cognitive Behavioral Therapy for Insomnia (CBT-I) | Combination | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 3 | 1 | 4 |
| White | 47 | 49 | 49 | 145 |
| More than one race | 1 | 1 | 0 | 2 |
| Unknown or Not Reported | 1 | 0 | 2 | 3 |
| Region of Enrollment(participants) | Medication (Zolpidem or Trazodone) | Internet Cognitive Behavioral Therapy for Insomnia (CBT-I) | Combination | Total |
|---|---|---|---|---|
| United States | 49 | 54 | 52 | 155 |
| Medication preference(Participants) | Medication (Zolpidem or Trazodone) | Internet Cognitive Behavioral Therapy for Insomnia (CBT-I) | Combination | Total |
|---|---|---|---|---|
| Zolpidem | 11 | 10 | 11 | 32 |
| Trazodone | 38 | 44 | 41 | 123 |
| Insomnia Severity Index total score(score on a scale) | Medication (Zolpidem or Trazodone) | Internet Cognitive Behavioral Therapy for Insomnia (CBT-I) | Combination | Total |
|---|---|---|---|---|
| Mean | 18.1 ± 4.3 | 17.4 ± 3.7 | 18.9 ± 4.2 | 18.1 ± 4.1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Feb 2022 to primary completion in Jun 2024, 28 months.
Results were first posted in Feb 2025, 7 months after primary completion.
Of 53 non-industry phase 4 interventional studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 59. This study's 28 months is close to that.
Counting every sponsor, half of 58 studies reached it within 28 months; a quarter within 17 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Zolpidem · Trazodone
Sleep Initiation and Maintenance Disorders →
California Pacific Medical Center Research Institute